To determine the expression level of Myo1g in ALL, we initially quantified the mRNA expression of Myo1g in 9 samples of peripheral blood and 9 samples of bone marrow from the same patients, subsequently we analyzed peripheral blood samples from patients, we follow them during the course of the treatment (when possible), specifically we analyzed 102 patients at diagnostic, 70 at remission and 73 at consolidation and compared those levels with 17 pediatric controls by real time PCR, the expression of GAPDH was used as internal control. This evidence concerns the gene GAPDH and acute lymphoblastic leukemia.